Aspirin may be more effective in preventing colorectal adenomas in patients with higher BMI (United States)

Sangmi Kim, John A. Baron, Leila A. Mott, Carol A. Burke, Timothy R. Church, Gail E. McKeown-Eyssen, Bernard F. Cole, Robert W. Haile, Robert S. Sandler

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Obesity is a risk factor for colon cancer, possibly due to elevated levels of circulating cytokines derived from adipose tissue. Aspirin, which may affect the levels of these cytokines, has been shown in randomized controlled trials to decrease the risk of colorectal adenomas. We hypothesized that the chemopreventive effect of aspirin might be greater in individuals with higher body mass index (BMI). Data were available from the Aspirin/Folate Polyp Prevention Study, a randomized controlled trial of aspirin and folic acid to prevent recurrent colorectal adenomas. Obesity was defined as BMI ≥ 30 (kg/m2), overweight as BMI of 25-29 (kg/m2) and normal weight as BMI <25 (kg/m2). For the analysis of the effect of aspirin on the recurrence of colorectal adenoma by BMI, we computed risk ratios for aspirin versus placebo within the three BMI strata using a modified Poisson model. Overall the risk reduction of adenomas with a daily dose of 325 mg aspirin was greater among subjects with higher BMI. Among obese subjects the risk ratio (RR) for advanced adenomas compared with placebo was 0.44 (95% CI 0.17-1.10), versus RR = 1.23 (95% CI 0.55-2.77) among those with normal weight. However, 81 mg aspirin daily did not interact with BMI to modify the risk of adenomas in such a fashion. The more pronounced effect of 325 mg aspirin in individuals with higher BMI suggests a possible protective role of anti-inflammatory aspirin against increased adipose-driven cytokines among obese subjects.

Original languageEnglish (US)
Pages (from-to)1299-1304
Number of pages6
JournalCancer Causes and Control
Volume17
Issue number10
DOIs
StatePublished - Dec 1 2006

Fingerprint

Adenoma
Aspirin
Body Mass Index
Odds Ratio
Cytokines
Folic Acid
Randomized Controlled Trials
Obesity
Placebos
Weights and Measures
Risk Reduction Behavior
Polyps
Colonic Neoplasms
Adipose Tissue
Anti-Inflammatory Agents
Recurrence

Keywords

  • Aspirin
  • Body mass index
  • Colorectal adenomatous

ASJC Scopus subject areas

  • Oncology
  • Epidemiology
  • Cancer Research

Cite this

Kim, S., Baron, J. A., Mott, L. A., Burke, C. A., Church, T. R., McKeown-Eyssen, G. E., ... Sandler, R. S. (2006). Aspirin may be more effective in preventing colorectal adenomas in patients with higher BMI (United States). Cancer Causes and Control, 17(10), 1299-1304. https://doi.org/10.1007/s10552-006-0075-x

Aspirin may be more effective in preventing colorectal adenomas in patients with higher BMI (United States). / Kim, Sangmi; Baron, John A.; Mott, Leila A.; Burke, Carol A.; Church, Timothy R.; McKeown-Eyssen, Gail E.; Cole, Bernard F.; Haile, Robert W.; Sandler, Robert S.

In: Cancer Causes and Control, Vol. 17, No. 10, 01.12.2006, p. 1299-1304.

Research output: Contribution to journalArticle

Kim, S, Baron, JA, Mott, LA, Burke, CA, Church, TR, McKeown-Eyssen, GE, Cole, BF, Haile, RW & Sandler, RS 2006, 'Aspirin may be more effective in preventing colorectal adenomas in patients with higher BMI (United States)', Cancer Causes and Control, vol. 17, no. 10, pp. 1299-1304. https://doi.org/10.1007/s10552-006-0075-x
Kim, Sangmi ; Baron, John A. ; Mott, Leila A. ; Burke, Carol A. ; Church, Timothy R. ; McKeown-Eyssen, Gail E. ; Cole, Bernard F. ; Haile, Robert W. ; Sandler, Robert S. / Aspirin may be more effective in preventing colorectal adenomas in patients with higher BMI (United States). In: Cancer Causes and Control. 2006 ; Vol. 17, No. 10. pp. 1299-1304.
@article{d263f664e0204ad8b78fe220d357a18a,
title = "Aspirin may be more effective in preventing colorectal adenomas in patients with higher BMI (United States)",
abstract = "Obesity is a risk factor for colon cancer, possibly due to elevated levels of circulating cytokines derived from adipose tissue. Aspirin, which may affect the levels of these cytokines, has been shown in randomized controlled trials to decrease the risk of colorectal adenomas. We hypothesized that the chemopreventive effect of aspirin might be greater in individuals with higher body mass index (BMI). Data were available from the Aspirin/Folate Polyp Prevention Study, a randomized controlled trial of aspirin and folic acid to prevent recurrent colorectal adenomas. Obesity was defined as BMI ≥ 30 (kg/m2), overweight as BMI of 25-29 (kg/m2) and normal weight as BMI <25 (kg/m2). For the analysis of the effect of aspirin on the recurrence of colorectal adenoma by BMI, we computed risk ratios for aspirin versus placebo within the three BMI strata using a modified Poisson model. Overall the risk reduction of adenomas with a daily dose of 325 mg aspirin was greater among subjects with higher BMI. Among obese subjects the risk ratio (RR) for advanced adenomas compared with placebo was 0.44 (95{\%} CI 0.17-1.10), versus RR = 1.23 (95{\%} CI 0.55-2.77) among those with normal weight. However, 81 mg aspirin daily did not interact with BMI to modify the risk of adenomas in such a fashion. The more pronounced effect of 325 mg aspirin in individuals with higher BMI suggests a possible protective role of anti-inflammatory aspirin against increased adipose-driven cytokines among obese subjects.",
keywords = "Aspirin, Body mass index, Colorectal adenomatous",
author = "Sangmi Kim and Baron, {John A.} and Mott, {Leila A.} and Burke, {Carol A.} and Church, {Timothy R.} and McKeown-Eyssen, {Gail E.} and Cole, {Bernard F.} and Haile, {Robert W.} and Sandler, {Robert S.}",
year = "2006",
month = "12",
day = "1",
doi = "10.1007/s10552-006-0075-x",
language = "English (US)",
volume = "17",
pages = "1299--1304",
journal = "Cancer Causes and Control",
issn = "0957-5243",
publisher = "Springer Netherlands",
number = "10",

}

TY - JOUR

T1 - Aspirin may be more effective in preventing colorectal adenomas in patients with higher BMI (United States)

AU - Kim, Sangmi

AU - Baron, John A.

AU - Mott, Leila A.

AU - Burke, Carol A.

AU - Church, Timothy R.

AU - McKeown-Eyssen, Gail E.

AU - Cole, Bernard F.

AU - Haile, Robert W.

AU - Sandler, Robert S.

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Obesity is a risk factor for colon cancer, possibly due to elevated levels of circulating cytokines derived from adipose tissue. Aspirin, which may affect the levels of these cytokines, has been shown in randomized controlled trials to decrease the risk of colorectal adenomas. We hypothesized that the chemopreventive effect of aspirin might be greater in individuals with higher body mass index (BMI). Data were available from the Aspirin/Folate Polyp Prevention Study, a randomized controlled trial of aspirin and folic acid to prevent recurrent colorectal adenomas. Obesity was defined as BMI ≥ 30 (kg/m2), overweight as BMI of 25-29 (kg/m2) and normal weight as BMI <25 (kg/m2). For the analysis of the effect of aspirin on the recurrence of colorectal adenoma by BMI, we computed risk ratios for aspirin versus placebo within the three BMI strata using a modified Poisson model. Overall the risk reduction of adenomas with a daily dose of 325 mg aspirin was greater among subjects with higher BMI. Among obese subjects the risk ratio (RR) for advanced adenomas compared with placebo was 0.44 (95% CI 0.17-1.10), versus RR = 1.23 (95% CI 0.55-2.77) among those with normal weight. However, 81 mg aspirin daily did not interact with BMI to modify the risk of adenomas in such a fashion. The more pronounced effect of 325 mg aspirin in individuals with higher BMI suggests a possible protective role of anti-inflammatory aspirin against increased adipose-driven cytokines among obese subjects.

AB - Obesity is a risk factor for colon cancer, possibly due to elevated levels of circulating cytokines derived from adipose tissue. Aspirin, which may affect the levels of these cytokines, has been shown in randomized controlled trials to decrease the risk of colorectal adenomas. We hypothesized that the chemopreventive effect of aspirin might be greater in individuals with higher body mass index (BMI). Data were available from the Aspirin/Folate Polyp Prevention Study, a randomized controlled trial of aspirin and folic acid to prevent recurrent colorectal adenomas. Obesity was defined as BMI ≥ 30 (kg/m2), overweight as BMI of 25-29 (kg/m2) and normal weight as BMI <25 (kg/m2). For the analysis of the effect of aspirin on the recurrence of colorectal adenoma by BMI, we computed risk ratios for aspirin versus placebo within the three BMI strata using a modified Poisson model. Overall the risk reduction of adenomas with a daily dose of 325 mg aspirin was greater among subjects with higher BMI. Among obese subjects the risk ratio (RR) for advanced adenomas compared with placebo was 0.44 (95% CI 0.17-1.10), versus RR = 1.23 (95% CI 0.55-2.77) among those with normal weight. However, 81 mg aspirin daily did not interact with BMI to modify the risk of adenomas in such a fashion. The more pronounced effect of 325 mg aspirin in individuals with higher BMI suggests a possible protective role of anti-inflammatory aspirin against increased adipose-driven cytokines among obese subjects.

KW - Aspirin

KW - Body mass index

KW - Colorectal adenomatous

UR - http://www.scopus.com/inward/record.url?scp=33751119026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751119026&partnerID=8YFLogxK

U2 - 10.1007/s10552-006-0075-x

DO - 10.1007/s10552-006-0075-x

M3 - Article

VL - 17

SP - 1299

EP - 1304

JO - Cancer Causes and Control

JF - Cancer Causes and Control

SN - 0957-5243

IS - 10

ER -